Santen Pharmaceutical Co (Santen Pharmaceutical Co) ROCE % : 12.10% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Santen Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 12.10%.

Santen Pharmaceutical Co ROCE % Historical Data

The historical data trend for Santen Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co ROCE % Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

13.68

10.43

3.93

10.22

-1.16

Santen Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															10.16	7.82	15.09	13.33	12.10

Santen Pharmaceutical Co ROCE % Calculation

Santen Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-32.17	/	( ( (3879.12 - 808.088)	+	(3151.021 - 669.618) )	/ 2 )
	=	-32.17	/	( (3071.032	+	2481.403)	/ 2 )
	=	-32.17	/	2776.2175
	=	-1.16 %

Santen Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	283.008	/	( ( (2888.052 - 548.432)	+	(2971.354 - 635.068) )	/ 2 )
	=	283.008	/	( ( 2339.62	+	2336.286 )	/ 2 )
	=	283.008	/	2337.953
	=	12.10 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Santen Pharmaceutical Co (OTCPK:SNPHY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Santen Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020